Invasive Candidiasis clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
A Study of Experimental Rezafungin Compared to Caspofungin For Candidemia and/or Invasive Candidiasis (yeast infection in blood)
open to eligible people ages 18 years and up
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
at UC Davis
Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases
open to eligible people ages 18 years and up
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment.
at UC Davis
Last updated: